Baseline characteristics
| . | Total (N = 78) . |
|---|---|
| Age, median (range) y | 61 (39-70) |
| Age group, y | |
| ≤60 | 34 (44%) |
| >60 | 44 (56%) |
| Sex | |
| Male | 43 (55%) |
| Female | 35 (45%) |
| Race | |
| White | 67 (87%) |
| Other | 10 (13%) |
| Diagnosis | |
| ALL | 3 (4%) |
| AML | 19 (24%) |
| MDS | 21 (27%) |
| Myelofibrosis | 31 (40%) |
| CML | 3 (4%) |
| Multiple myeloma | 1 (1%) |
| Donor | |
| HLA-matched sibling | 29 (37%) |
| HLA-matched 8-of-8 unrelated | 49 (63%) |
| Graft source | |
| Peripheral blood progenitor cells | 73 (94%) |
| Bone marrow | 5 (6%) |
| GVHD prophylaxis | |
| PTCy/tacro | 40 (51%) |
| PTCy/tacro/MMF | 38 (49%) |
| Refined DRI | |
| Low | 3 (4%) |
| Intermediate | 58 (74%) |
| High | 17 (22%) |
| HCT-CI | |
| 0 | 11(14%) |
| 1-2 | 33 (42%) |
| 3-4 | 23 (30%) |
| ≥5 | 11 (14%) |
| Karnofsky performance status | |
| 70 | 7 (9%) |
| 80 | 22 (29%) |
| 90 | 24 (31%) |
| 100 | 24 (31%) |
| . | Total (N = 78) . |
|---|---|
| Age, median (range) y | 61 (39-70) |
| Age group, y | |
| ≤60 | 34 (44%) |
| >60 | 44 (56%) |
| Sex | |
| Male | 43 (55%) |
| Female | 35 (45%) |
| Race | |
| White | 67 (87%) |
| Other | 10 (13%) |
| Diagnosis | |
| ALL | 3 (4%) |
| AML | 19 (24%) |
| MDS | 21 (27%) |
| Myelofibrosis | 31 (40%) |
| CML | 3 (4%) |
| Multiple myeloma | 1 (1%) |
| Donor | |
| HLA-matched sibling | 29 (37%) |
| HLA-matched 8-of-8 unrelated | 49 (63%) |
| Graft source | |
| Peripheral blood progenitor cells | 73 (94%) |
| Bone marrow | 5 (6%) |
| GVHD prophylaxis | |
| PTCy/tacro | 40 (51%) |
| PTCy/tacro/MMF | 38 (49%) |
| Refined DRI | |
| Low | 3 (4%) |
| Intermediate | 58 (74%) |
| High | 17 (22%) |
| HCT-CI | |
| 0 | 11(14%) |
| 1-2 | 33 (42%) |
| 3-4 | 23 (30%) |
| ≥5 | 11 (14%) |
| Karnofsky performance status | |
| 70 | 7 (9%) |
| 80 | 22 (29%) |
| 90 | 24 (31%) |
| 100 | 24 (31%) |
ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MMF, mycophenolate mofetil; tacro, tacrolimus.